Biotech By Adam Feuerstein Rafael Pharma drug fails to prolong survival of patients with pancreatic cancer in large study
Health By Megan Molteni Public-private partnership launched to accelerate gene therapies for rare diseases
Biotech By Jon Chesto — Boston Globe As scientific labs replace offices, pushback is mounting from wary neighbors
Biotech By Adam Feuerstein 6 things to know before the readout of Rafael Pharma’s pancreatic cancer drug study
Biotech By Damian Garde Cortexyme’s bacteria-fighting Alzheimer’s drug fails primary goal, but company sees a path forward
Biotech By Kate Sheridan Licensing biotech breakthroughs is a contentious, painful slog. Can the process be fixed?
Biotech By Megan Molteni Eight years after a landmark Supreme Court ruling on DNA ownership, its ramifications are becoming clearer
Biotech By Damian Garde and Adam Feuerstein Biogen’s Aduhelm sales fall dramatically below Wall Street’s expectations
Biotech By Damian Garde and Matthew Herper Atea’s antiviral pill fails to clear Covid-19, forcing a re-think
Adam's Take By Adam Feuerstein An FDA rejection derails Omeros, exposing the empty promises of its CEO
Biotech By Adam Feuerstein Biogen drug for rare form of ALS fails pivotal study — another setback for fatal disease with few treatments
Biotech By Adam Feuerstein New data on CRISPR Therapeutics’ off-the-shelf CAR-T cancer therapy shows more remissions, no major safety issues
Biotech By Adam Feuerstein FDA halts Allogene blood cancer trials after patient found to have ‘chromosomal abnormality’
Biotech By Adam Feuerstein Disappointing tumor responses, more side effects, seen with latest Amgen KRAS combination studies
Biotech By Matthew Herper Backed with $500 million, a startup aims to rethink psychiatric drug development
Biotech By Kate Sheridan Vedanta touts positive new data for its C. diff microbiome therapeutic — but is it too late?
Biotech By Adam Feuerstein The biotech scorecard for the fourth quarter: 19 stock-moving events to watch
A STAT Investigation By Megan Molteni and Mario Aguilar Inside the downfall of longevity crusader Aubrey de Grey — and the cult of personality that concealed a pattern of harassment
Biotech By Kate Sheridan In the ‘fail fast’ world of biotech, ‘offboarding’ is just as important as onboarding
Biotech By Matthew Herper With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant
Biotech By Adam Feuerstein Editas CRISPR treatment improved vision for one patient, but not others, early data show
Biotech By Kate Sheridan Graduate students launch an entrepreneurship program to bring new faces to biotech
Biotech By Adam Feuerstein Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard
Exclusive By Adam Feuerstein and Damian Garde Biogen’s Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures
Biotech By Adam Feuerstein Is a Beyondspring drug helping lung cancer patients live longer? Study results trigger debate
